Baird Maintains Outperform on Castle Biosciences, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) and keeps the price target at $34.
July 05, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) and keeps the price target at $34.
The reaffirmation of an Outperform rating and a $34 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100